Aurora Cannabis Inc Earnings - Q1 2026 Analysis & Highlights
Aurora Cannabis reported strong fiscal 2026 results driven by global medical cannabis expansion, strategic portfolio optimization, and disciplined financial management, while navigating near-term headwinds from Canadian reimbursement changes and positioning for international growth through targeted acquisitions and capacity expansion.
Key Financial Results
Net revenue rose 11% to CAD 321 million in fiscal 2026, exceeding the top end of guided range by CAD 8 million, with approximately 55% generated outside of Canada.
Adjusted gross margin expanded to 64%, reflecting benefits from investments in the value chain, science, plant genetics, operational efficiencies, and capacity improvements.
Adjusted EBITDA grew 32% year-over-year to CAD 54 million.
Adjusted net income improved by more than CAD 12 million in fiscal 2026.
Strong balance sheet with CAD 165 million in cash and cash equivalents and no debt at year-end.
Q4 2026 net revenue increased 10% to CAD 84.8 million, driven by 14% growth in global medical cannabis revenue, including 19% international growth.
Q4 2026 adjusted gross margins reached 60%, with adjusted EBITDA of CAD 9.2 million and adjusted net income of CAD 5.6 million.
Free cash flow was CAD 0.3 million in Q4 2026 compared to CAD 5.2 million in the prior year.
Business Segment Results
Medical cannabis net revenue rose 14% to CAD 77.1 million in Q4 2026, inclusive of 19% international growth, setting new records for Canadian and international net revenue.
Medical cannabis comprised 91% of net revenue in Q4 2026 compared to 88% in the prior year, representing the majority of adjusted gross profit.
Adjusted gross margin for medical cannabis held strong at 66% in Q4 2026, though decreased from prior year due to sale of lower-margin products and strategic price reductions in certain markets.
Consumer cannabis net revenue was CAD 3.6 million in Q4 2026, down from CAD 8.2 million, as the company wound down the segment to allocate cannabis flower to higher-margin medical cannabis.
Germany was the biggest contributor to double-digit international revenue growth in fiscal 2026, benefiting from strong commercial execution and well-established reputation with wholesalers, distributors, and pharmacists.
Poland was the second largest contributor to international growth in fiscal 2026 after Germany, supported by strong commercial execution and successful navigation of the shift from telehealth-driven to clinic-based prescribing.
Australia continues to hold a key leadership position, with the company actively shifting sales mix towards core and premium products in response to growing interest from prescribing physicians and patients.
Capital Allocation
Acquired Safari Flower Company for approximately CAD 26.5 million, an established Canadian-based EU GMP certified cannabis cultivator and manufacturer with a 59,000 square foot indoor cultivation and manufacturing facility in Ontario.
Divested controlling stake in Bevo, the lower-margin plant propagation business, to deploy capital more effectively and enhance profitability.
Initiated exit from certain lower-margin Canadian consumer segment markets, expected to complete by end of September, carrying one-time cash impacts during the quarter.
Access to shelf prospectus filed February 14 through which the company can issue various securities during the 25-month period it remains effective.
At-the-market program allows issuance of up to $100 million of common shares.
Industry Trends and Dynamics
Global medical cannabis market opportunity estimated at CAD 9 billion, with Aurora positioned to convert this into sustained shareholder returns.
Germany represents the largest and fastest-growing medical cannabis market by tonnage among international markets, with strict GMP standards and well-developed ecosystem including direct-to-patient delivery, telehealth systems, proper manufacturing standards, and strong regulators.
Increased price pressure in Germany concentrated in the value segment, while core and premium categories represent most of volume and have maintained strong pricing.
Poland experiencing growth following successful navigation of shift from telehealth-driven to clinic-based prescribing, with recent increases in annual import limits strengthening growth outlook.
Potential legislative developments in Germany expected in fall, including potential reduction in telehealth requirements and possible prohibition on mail delivery of medical cannabis products.
Potential developments in markets such as France, Ukraine, Switzerland, Spain, and Austria present expansion opportunities for Aurora.
Competitive Landscape
Aurora is market leader in Canada, Germany, Australia, and Poland, the four largest nationally legal medical cannabis markets.
Only a small group of producers, including Aurora, hold certifications required to ship directly into European and Australian medical markets.
One of three active in-country producers of medical cannabis in Germany, carrying production and R&D license under German cannabis law, positioning the company to serve all medical markets in Europe.
Two of Aurora's proprietary cultivars ranked number 1 and number 3 by sales in the most recent quarter in Germany.
New competitors entering German market creating increased price pressure, though largely concentrated in value segment where Aurora has limited exposure.
Diversified product portfolio, strong brand equity, and disciplined pricing strategy position Aurora well to maintain leadership as competition evolves.
Canadian market characterized by dependable market share, high barriers to entry, regulatory expertise, investment in technology and distribution, and commitment to science, testing, and compliance.
Consolidated competitive structure in Germany with approximately 4 companies capturing 50% market share, compared to approximately 30 companies needed to achieve 50% share in Canada.
Macroeconomic Environment
Changes to federal reimbursement program effective April 1 expected to impact top line and adjusted gross margins beginning in fiscal 2027.
VAC reimbursement rate reduction of approximately 30% for reimbursed medical cannabis products effective April 1.
Inflation-related labor costs and increased head count to support international revenue contributed to adjusted SG&A increases.
Decrease in foreign exchange gains and interest income impacted Q4 2026 adjusted net income.
Growth Opportunities and Strategies
Strategic focus on global medical cannabis as the most attractive and durable segment of the industry, anchored by leadership in nationally legal markets.
Major expansion at Leuna facility in Germany to increase capacity, improve product quality, and drive cost efficiency, with completion expected in first half of fiscal 2027 and intention to double annual flower output.
40% increase in EU GMP capacity over the last five years through investments in plant science and operational expertise.
Expansion of medical cannabis portfolio across Canada, Europe, Australia, and New Zealand through launches of dried flower, pre-rolls, and edibles designed to meet patient and prescriber demand.
Integrated model of manufacturing and distribution drives lower production costs through higher yields, potency improvements, and ongoing operational efficiencies.
Investments in plant science providing new disease-resistant cultivars that deliver higher yields per square foot and consistently achieve high potency results.
Patented genetics with disease resistance, particularly on powdery mildew, recently announced as core competitive advantage.
Genetic system focused on four key areas: commercial aspects (yield, potency, unique attributes), key attributes beyond potency (unique terpenes), consistency for market registration, and disease resistance.
Considering reevaluation of US strategy following cannabis rescheduling developments, with potential opportunities in research, partnerships, and import/export.
Three potential buckets for US opportunity: opening to research, potential partnerships applying GMP and medical-grade standards, and potential import and export of products.
Potential for partnerships with pharmaceutical companies as medical cannabis market expands globally, leveraging pharmaceutical industry expertise in development, registration, placement, and physician interaction.
Financial Guidance and Outlook
Total net revenue expected to decline in fiscal 2027 and be more in line with cannabis net revenue result in fiscal 2025, following changes in Canadian medical partially offset by international growth driven by Germany and Poland.
Adjusted gross margins expected to be in the mid to high-50s in fiscal 2027, driven by higher revenue contributions from Europe and exit from lower-margin businesses, partially offset by lower margins in Canadian medical.
Adjusted SG&A expected to remain broadly in line with prior fiscal year.
Adjusted EBITDA expected to vary quarter over quarter, leading to lower annual adjusted EBITDA compared to prior fiscal year due to revision in reimbursed pricing.
Safari Flower expected to deliver positive adjusted EBITDA contributions in fiscal 2027 with incremental benefits in fiscal 2028 and beyond.
Fiscal 2027 characterized as a reset year shaped by changes to reimbursed pricing in Canadian medical that can only be partially offset by international growth.
Company purposely investing in international business through strategic sales initiatives and EU GMP capacity expansion to support growth in most profitable markets over next few quarters.
Medical Cannabis Market Position and Strategy
Aurora is one of Canada's largest global medical cannabis companies and leading exporter of medical cannabis with world-class GMP certified facilities.
Majority of manufacturing capacity produced within EU GMP and TGA GMP certified facilities operating under strict international standards.
Direct-to-patient model in Canada historically allowed Aurora to achieve sustainable gross profit margins without reliance on provincial wholesalers or private retailers.
Company recognizes near-term impact of shift in pricing and believes it has capabilities, financial resources, and resilience to successfully navigate Canadian reimbursement changes while continuing to invest in international opportunities.
Medical cannabis net revenue in Canada grew annually due to higher sales from insured patients who benefited from broader portfolio assortment.
Company expects to continue growing market share in Canadian medical despite reimbursement rate changes, as overall patient pool and benefits remain solid and steady.
